Phase 2 Single Center, Open-Label Study to Assess Immunogenicity and Safety of 5 Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX)in Smokers.

Trial Profile

Phase 2 Single Center, Open-Label Study to Assess Immunogenicity and Safety of 5 Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX)in Smokers.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 May 2012

At a glance

  • Drugs Nicotine abuse vaccine (Primary)
  • Indications Smoking withdrawal; Substance-related disorders
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 08 May 2012 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
    • 08 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Aug 2008 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top